110 Results for "

extracellular domain

" in MedChemExpress (MCE) Product Catalog:
Products (110)

110 Results for "extracellular domain" in MCE Product Catalog:

23
23 Publications Verification
Cat. No.: HY-101084
CAS No.: 113104-25-9
Purity:  ≥98.0%
NSC 228155 is an activator of EGFR, binds to the extracellular region of EGFR and enhance tyrosine phosphorylation of EGFR . NSC 228155 is also a potent inhibitor of KIX-KID interaction, inhibits kinase-inducible domain (KID) from CREB and KID-interacting domain (KIX) from CBP, with an IC50 of 0.36 μM .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-12316
CAS No.: 516-72-3
Purity:  99.29%
Synonyms: 20α-Hydroxycholesterol
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC50 of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-153268
CAS No.: 2607829-38-7
Purity:  99.03%
Synonyms: BDTX-1535; EGFR-IN-76
Target:  

EGFR

Silevertinib (BDTX-1535) is an irreversible, brain-penetrant, selective and orally active EGFR inhibitor with wild-type EGFR-sparing. Silevertinib targets key EGFR resistance mutations, including the kinase domain (C797S, L718Q, G724S, S768I), extracellular domain (EGFRvIII, A289X), and EGFR amplification. Silevertinib exerts anti-tumor activity with well tolerated in vivo. Silevertinib can be used for non-small cell lung cancer (NSCLC) and glioblastoma (GBM) research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108829
CAS No.: 332348-12-6
Purity:  ≥99.0%
Synonyms: CTLA4lg; BMS-188667

Target:  

CTLA-4

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12283
CAS No.: 156722-18-8
Purity:  99.03%
Synonyms: PST 2238
Target:  

Na+/K+ ATPase RSV

Research Areas:  

Cardiovascular Disease

Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na +,K +-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108829A
CAS No.: 332348-12-6
Purity:  95.00%
Synonyms: CTLA4lg (powder); BMS-188667 (powder); Orencia
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13242
CAS No.: 1258861-20-9
Purity:  99.92%
Synonyms: LY2940680
Target:  

Smo Gli

Research Areas:  

Cancer

Taladegib is a Smoothened (SMO) antagonist. Taladegib hydrochloride inhibits the Hedgehog signaling pathway, with an IC50 of 5.5 nM for suppressing GLI1 mRNA expression in DAOY cells and an IC50 of 7.6 nM in CGNP cell proliferation assays. Taladegib binds to the extracellular loop region (site 1) of the transmembrane domain of the SMO receptor, competes with cyclopamine for SMO binding, and thereby inhibits Gli-dependent transcription. Taladegib can be used in studies of Hedgehog pathway-related cancers .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P71691
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TNC; Neuronectin; Prev. HXB; Cytotactin; Prev. DFNA56; Tenascin-C; TN; MGC167029; Tenascin; GMEM; Glioma-Associated-extracellular Matrix Antigen; TN-C; Deafness, Autosomal Dominant 56; JI; Tenascin-C Additional domain 1; Hexabrachion (Tenascin C, Cytotact
Species:  
Human
Source:  
E. coli
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13242A
CAS No.: 1258861-21-0
Synonyms: LY2940680 hydrochloride
Target:  

Smo Gli

Research Areas:  

Cancer

Taladegib (LY2940680) hydrochloride is a Smoothened (SMO) antagonist. Taladegib hydrochloride inhibits the Hedgehog signaling pathway, with an IC50 of 5.5 nM for suppressing GLI1 mRNA expression in DAOY cells and an IC50 of 7.6 nM in CGNP cell proliferation assays. Taladegib hydrochloride binds to the extracellular loop region (site 1) of the transmembrane domain of the SMO receptor, competes with cyclopamine for SMO binding, and thereby inhibits Gli-dependent transcription. Taladegib hydrochloride can be used in studies of Hedgehog pathway-related cancers .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99507
CAS No.: 1969309-56-5
Synonyms: MCLA-128; PB4188; R040517

Target:  

EGFR

Research Areas:  

Cancer

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-125399
CAS No.: 1366302-52-4
Purity:  99.74%
Synonyms: HBED-CC-PSMA
Research Areas:  

Cancer

PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99205
CAS No.: 1020264-78-1

Target:  

ADC Antibodies

Research Areas:  

Cancer

Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9968
CAS No.: 780758-10-3
Synonyms: h-R3

Target:  

EGFR

Research Areas:  

Cancer

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99165
CAS No.: 1036734-93-6

Target:  

IGF-1R TSH Receptor

Research Areas:  

Endocrinology

Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9920A
CAS No.: 947687-13-0

Target:  

VEGFR

Research Areas:  

Cancer

Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99437
CAS No.: 2367012-88-0
Synonyms: KN-026

Target:  

EGFR

Research Areas:  

Cancer

Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18377
CAS No.: 1420071-30-2
Synonyms: DR5 Activator
Target:  

TNF Receptor Apoptosis

Research Areas:  

Cancer

Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P700834
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNC; Neuronectin; Prev. HXB; Cytotactin; Prev. DFNA56; Tenascin-C; TN; MGC167029; Tenascin; GMEM; Glioma-Associated-extracellular Matrix Antigen; TN-C; Deafness, Autosomal Dominant 56; JI; Tenascin-C Additional domain 1; Hexabrachion (Tenascin C, Cytotact
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P700002
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TNC; Neuronectin; Prev. HXB; Cytotactin; Prev. DFNA56; Tenascin-C; TN; MGC167029; Tenascin; GMEM; Glioma-Associated-extracellular Matrix Antigen; TN-C; Deafness, Autosomal Dominant 56; JI; Tenascin-C Additional domain 1; Hexabrachion (Tenascin C, Cytotact
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P700002A
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNC; Neuronectin; Prev. HXB; Cytotactin; Prev. DFNA56; Tenascin-C; TN; MGC167029; Tenascin; GMEM; Glioma-Associated-extracellular Matrix Antigen; TN-C; Deafness, Autosomal Dominant 56; JI; Tenascin-C Additional domain 1; Hexabrachion (Tenascin C, Cytotact
Species:  
Mouse
Source:  
HEK293
loading...
    loading...